Key clinical point: Subcutaneous treatment with concizumab appears to significantly reduce bleeding rates in patients with hemophilia A and B.
Major finding: Among patients with hemophilia A or B with inhibitors, the mean annualized bleeding rate for all bleeds declined from 20.4 to 4.5.
Study details: Two phase 2 dose-escalation trials – explorer 4 and explorer 5 – of concizumab in hemophilia patients. The explorer 4 trial included 26 adults with hemophilia A or B with inhibitors. The explorer 5 trial included 36 adults with hemophilia A without inhibitors.
Disclosures: Novo Nordisk sponsored both studies. Dr. Astermark has received consultancies and research funding unrelated to the study.
Astermark J et al. 2019 ISTH Congress, Abstract LB 01.1.